ChemoCentryx/Vifor Change Tack On EU Avacopan Filing

 
• By Ian Schofield

ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.

Exchange
The EU avacopan CMA application has been swapped to a full MA. • Source: Shutterstock

More from Approvals

More from Product Reviews